Amneal Pharmaceuticals (AMRX): Price-to-Projected Revenue Ratio

Amneal Pharmaceuticals Inc (AMRX) - corporate logo

Amneal Pharmaceuticals (AMRX) is implementing ESG principles by reducing harmful emissions and water consumption. The future P/S dynamics for Amneal Pharmaceuticals on this GURU.Markets chart show that the parameter reaches 0.70. Business efficiency relies on optimized ground delivery of medications and a stable staff of high-class chemical technologists who ensure the development of the biosimilar portfolio.

AMRX amneal.com: Market Cap to Projected Revenue in the range 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for amneal.com (AMRX)

Summary company analytics:Amneal Pharmaceuticals Inc (AMRX)
Product sample of Amneal Pharmaceuticals

For Amneal Pharmaceuticals (AMRX), the current forward P/S ratio reflects market expectations for capitalization relative to projected revenue, confirming the effectiveness of scaling through the automation of generic drug production. This indicator measures the business's fundamental margin of safety, demonstrating the company's ability to maintain asset value amid changes in tax regimes or demand for specialized medications.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Perrigo Company PLC - Forward Price to Sales|Price-to-Projected Revenue Ratio alvotech.com|Forward P/S Multiple Liquidia Technologies|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP